Stanford, California 94305


Purpose:

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.


Criteria:

Inclusion Criteria: - Patients older than 18-year-old, diagnosed with cancer - Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them Exclusion Criteria: - Patients who cannot complete a PET/CT scan - Pregnant women - Healthy volunteers - Patients participating in other research studies The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.


NCT ID:

NCT00725387


Primary Contact:

Principal Investigator
Andrei Iagaru M.D
Stanford University


Backup Contact:

N/A


Location Contact:

Stanford, California 94305
United States

Andrei Iagaru
Phone: 650-736-2859
Email: aiagaru@stanford.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.